Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Lower Plasma β-Amyloid 1-42 Levels in Amnestic Mild Cognitive Impairment Compared to Healthy Individuals

The Indonesian Biomedical Journal · Vol. 16 No. 6 (2024) · hlm. 572–580

DOI
10.18585/inabj.v16i6.3404
ISSN
2085-3297, 2355-9179
Terbit
2024-12-23
Penerbit
Secretariat of The Indonesian Biomedical Journal
Bahasa
en
Lisensi
creativecommons.org/licenses/by-nc/4.0/

Abstrak

BACKGROUND: Amnestic mild cognitive impairment (aMCI) is strongly associated with an increased risk of progression to Alzheimer’s disease (AD). In AD, cerebrospinal fluid (CSF) β-Amyloid 1-42 levels are known to decrease, a pattern which is also observed in aMCI. While in AD, apolipoprotein E (ApoE) ε4 allele is known to be a genetic risk factor, the role of ApoE ε4 allele in modulating plasma β-Amyloid 1-42 levels in aMCI remains unclear. Therefore, this study was performed to evaluate plasma β-Amyloid 1-42 levels in aMCI patients compared to cognitively healthy individuals and investigate its association with ApoE ε4 allele.METHODS: A cross-sectional study involving 57 aMCI and 54 cognitively healthy control (HC) subjects was performed. Blood samples were taken from subjects from both groups for measurement of the plasma β-Amyloid 1-42 and ApoE ε4 allele. The plasma levels of β-Amyloid 1-42 were measured using an enzyme-linked immunosorbent assay (ELISA) methods, while the ApoE ε4 allele genotyping was conducted using polymerase chain reaction (PCR) techniques.RESULTS: Plasma β-Amyloid 1-42 in individuals with aMCI (23.9 pg/mL) was significantly lower than that in HC (25.3 pg/mL) with cut-off value of 24.6 pg/mL (AUC: 70.8%; 95% CI: 61.1–80.5%; p<0.001) sensitivity of 64.8%, and specificity of 71.9%. There was no significant association between plasma β-Amyloid 1-42 and the ApoE ε4 allele. However, plasma β-Amyloid 1-42 in ε4 carriers were lower than in ε4 non-carriers.CONCLUSION: Lower plasma β-Amyloid 1-42 levels were observed in aMCI patients compared to cognitively healthy individuals, suggesting its potential as a biomarker for identifying aMCI.KEYWORDS: blood biomarkers, amyloid beta peptides, amnestic mild cognitive impairment (aMCI)

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 130 tautan kepenulisan bersama · 60 lintas organisasi · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Universitas Airlangga
  • Bandung Institute of Technology
  • IPB University
  • National Brain Centre
  • Rumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo
  • Rumah Sakit Dokter Soetomo
  • University of Surabaya
  • Organisasi lain
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Kuntoro KuntoroUniversitas Airlangga3
Rachmah IndawatiUniversitas Airlangga2
Farapti FaraptiUniversitas Airlangga2
Chatarina Umbul WahyuniUniversitas Airlangga2
Lilis SulistyoriniUniversitas Airlangga2
Muhammad AminuddinRumah Sakit Dokter Soetomo2
Paulus Budiono NotopuroUniversitas Airlangga2
Abdul Hafid BajamalUniversitas Airlangga2
Valentinus BesinUniversity of Surabaya2
Mohammad Hasan MachfoedUniversitas Airlangga2
I Ketut SudianaUniversitas Airlangga2
Dwi - KuswantoUniversitas Airlangga1
Annisaa Wulida FurqoniaUniversitas Airlangga1
Diah RatnadewiIPB University1
Atik Choirul HidajahUniversitas Airlangga1
Ika Dewi AnaUniversitas Gadjah Mada1
Christofora Hanny WidjajaIPB University1
Anggraini BarlianBandung Institute of Technology1
Rizka Musdalifah AmsarBandung Institute of Technology1
Triati Dewi Kencana WunguBandung Institute of Technology1
Fedik Abdul RantamUniversitas Airlangga1
Romaniyanto RomaniyantoRSO Soeharso Surakarta1
Cita Rosita Sigit PrakoeswaUniversitas Airlangga1
Damayanti TinduhUniversitas Airlangga1
Dwikora Novembri UtomoUniversitas Airlangga1
Heri SurotoUniversitas Airlangga1
Ferdiansyah FerdiansyahUniversitas Airlangga1
Mochammad Bagus QomaruddinUniversitas Airlangga1
Apik Indarty MoedjionoHasanuddin University1
Nursalam NursalamUniversitas Airlangga1
Fery Agusman Motuho MendrofaUniversitas Karya Husada Semarang1
Hasan MachfoedUniversitas Airlangga1
Rachmad HargonoUniversitas Airlangga1
Bagus WidjonarkoDiponegoro University1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S2764892910, pertama di-harvest 19 Nov 2026, terakhir terlihat 19 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Lower Plasma β-Amyloid 1-42 Levels in Amnestic Mild Cognitive Impairment Compared to Healthy Individuals</dc:title><dc:creator>Cynthia Cynthia</dc:creator><dc:creator>Jusak Nugraha</dc:creator><dc:creator>Muhammad Hamdan</dc:creator><dc:creator>Hari Basuki Notobroto</dc:creator><dc:creator>Silvia Francina Lumempouw</dc:creator><dc:creator>Rahajuningsih S Dharma</dc:creator><dc:subject>amnestic mild cognitive impairment</dc:subject><dc:subject>APOE ε4</dc:subject><dc:subject>blood biomarkers</dc:subject><dc:subject>Alzheimer's disease risk</dc:subject><dc:subject>biomarker cut-off values</dc:subject><dc:description xml:lang="en">BACKGROUND: Amnestic mild cognitive impairment (aMCI) is strongly associated with an increased risk of progression to Alzheimer’s disease (AD). In AD, cerebrospinal fluid (CSF) β-Amyloid 1-42 levels are known to decrease, a pattern which is also observed in aMCI. While in AD, apolipoprotein E (ApoE) ε4 allele is known to be a genetic risk factor, the role of ApoE ε4 allele in modulating plasma β-Amyloid 1-42 levels in aMCI remains unclear. Therefore, this study was performed to evaluate plasma β-Amyloid 1-42 levels in aMCI patients compared to cognitively healthy individuals and investigate its association with ApoE ε4 allele.METHODS: A cross-sectional study involving 57 aMCI and 54 cognitively healthy control (HC) subjects was performed. Blood samples were taken from subjects from both groups for measurement of the plasma β-Amyloid 1-42 and ApoE ε4 allele. The plasma levels of β-Amyloid 1-42 were measured using an enzyme-linked immunosorbent assay (ELISA) methods, while the ApoE ε4 allele genotyping was conducted using polymerase chain reaction (PCR) techniques.RESULTS: Plasma β-Amyloid 1-42 in individuals with aMCI (23.9 pg/mL) was significantly lower than that in HC (25.3 pg/mL) with cut-off value of 24.6 pg/mL (AUC: 70.8%; 95% CI: 61.1–80.5%; p&lt;0.001) sensitivity of 64.8%, and specificity of 71.9%. There was no significant association between plasma β-Amyloid 1-42 and the ApoE ε4 allele. However, plasma β-Amyloid 1-42 in ε4 carriers were lower than in ε4 non-carriers.CONCLUSION: Lower plasma β-Amyloid 1-42 levels were observed in aMCI patients compared to cognitively healthy individuals, suggesting its potential as a biomarker for identifying aMCI.KEYWORDS: blood biomarkers, amyloid beta peptides, amnestic mild cognitive impairment (aMCI)</dc:description><dc:publisher>Secretariat of The Indonesian Biomedical Journal</dc:publisher><dc:date>2024-12-23</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:format>application/pdf</dc:format><dc:identifier>https://doi.org/10.18585/inabj.v16i6.3404</dc:identifier><dc:identifier>10.18585/inabj.v16i6.3404</dc:identifier><dc:source>The Indonesian Biomedical Journal; Vol 16 No 6 (2024); 572-580</dc:source><dc:source>2085-3297</dc:source><dc:source>2355-9179</dc:source><dc:language>en</dc:language><dc:relation>https://inabj.org/index.php/ibj/article/download/3404/749</dc:relation><dc:rights>https://creativecommons.org/licenses/by-nc/4.0/</dc:rights></oai_dc:dc>